ZOLL Announces Sole Source Contract with Universal Health Services, Inc.
ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced a three-year, sole source contract with Universal Health Services, Inc. (UHS), one of the largest hospital management companies. This contract authorizes ZOLLÂ’s direct sales force to sell its complete line of defibrillators to all UHS facilities, which have already purchased more than 150 ZOLL defibrillators to date.
(PRWEB) June 10, 2004
ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, today announced a three-year, sole source contract with Universal Health Services, Inc. (UHS), one of the largest hospital management companies. This contract authorizes ZOLLÂ’s direct sales force to sell its complete line of defibrillators to all UHS facilities, which have already purchased more than 150 ZOLL defibrillators to date.
With approximately 26,000 employees, UHS operates more than 100 medical facilities in the U. S., Puerto Rico, and France. UHS consists of behavioral health hospitals, acute care and ambulatory facilities, and radiation centers. “We require medical devices that clearly demonstrate an ability to improve the quality and outcome of patient care,” said Clark Saylor, Director of Purchasing for UHS. “The significant clinical support ZOLL provided for its products contributed to the decision to award ZOLL this sole source contract."
“Centralizing the purchasing process with UHS streamlines our sales cycle and builds on the success of our M Series™ defibrillators,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “It also allows us to further expand the market for our automated external defibrillator, the ZOLL AED Plus™. The AED Plus, which is suitable for clinical and non-clinical settings, meets the needs of any early defibrillation program and better prepares UHS facilities for sudden cardiac arrest wherever it may occur.”
When a victim collapses from sudden cardiac arrest, rescuers do not know whether defibrillation or CPR is the appropriate therapy until an AED is attached and the victimÂ’s heart is analyzed. About half of all sudden collapsed victims initially require defibrillation. For other victims however, who may have non-shockable heart rhythms, the critical action for survival is effective CPR.
The ZOLL AED Plus is the only AED that help rescuers perform effective CPR because it allows them to see and hear how well they are performing the rate and depth of chest compressions during CPR. This real-time feedback mechanism makes the ZOLL AED Plus the only AED that can help assess and treat nearly every sudden cardiac arrest victim, making it the only Full-Rescue AED available today.
About Universal Health Services, Inc.
Universal Health Services, Inc. is one of the nation's largest hospital companies, operating acute care and behavioral health hospitals, and ambulatory centers nationwide, in Puerto Rico and in France. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE: UHT).
About ZOLL Medical Corporation
ZOLL Medical Corporation (NASDAQ: ZOLL) designs, manufactures, markets, or sells non-invasive resuscitation devices and software solutions. They include pacing and defibrillation devices (ZOLL’s M Series™ and AED Plus™, and LIFECOR, Inc.’s LifeVest™ Wearable Defibrillator); circulatory assist devices (Advanced Circulatory Systems, Inc.’s ResQPOD™ Circulatory Enhancer and Revivant Corporation’s AutoPulse™); and a fluid resuscitation product called the Power Infuser®, manufactured by Infusion Dynamics, a division of ZOLL. These devices help healthcare professionals, emergency medical service providers, and first responders diagnose and treat victims of trauma, as well as sudden cardiac arrest.
Additionally, through its subsidiary ZOLL Data Systems, ZOLL designs and markets software that automates the collection and management of both clinical and non-clinical data. With direct operations, international offices, and business partners in all of the worldÂ’s major markets, ZOLL markets and sells its products in more than 140 countries. For more information, visit www. zoll. com or call +1 (978) 421-9655.
Certain statements contained in this press release, including statements regarding the anticipated development of the CompanyÂ’s business, our ability to differentiate our products from others on the market, and other statements contained herein regarding matters that are not historical facts, are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled "Risk Factors" in the CompanyÂ’s Quarterly Report on Form 10-Q filed with the SEC on May 19, 2004.
Copyright © 2004 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AED Plus and M Series are trademarks of ZOLL Medical Corporation. The LifeVest System is a trademark of LIFECOR, Inc. The ResQPOD is a trademark of Advance Circulatory Systems, Inc. The AutoPulse Resuscitation System is a trademark of Revivant Corporation. Power Infuser is a registered trademark of Infusion Dynamics, Inc. ZOLL is a registered trademark of ZOLL Medical Corporation. All trademarks are property of their respective owners.
###
